Market Overview

Stifel Nicolaus Initiates CoLucid Pharmaceuticals With Buy


Analysts at Stifel Nicolaus initiated coverage on CoLucid Pharmaceuticals Inc (NASDAQ: CLCD) with a Buy rating.

The target price for CoLucid Pharmaceuticals is set to $15.

CoLucid Pharmaceuticals' shares rose 4.61 percent to $9.08 in pre-market trading.

Latest Ratings for CLCD

Jan 2017DowngradesOverweightEqual-Weight
Dec 2016Initiates Coverage OnBuy
Dec 2016Initiates Coverage OnOverweight

View More Analyst Ratings for CLCD
View the Latest Analyst Ratings

Posted-In: Stifel NicolausInitiation Analyst Ratings


Related Articles (CLCD)

View Comments and Join the Discussion!

Latest Ratings

ABBBarclaysInitiates Coverage On
DPLOWilliam BlairUpgrades
SUPVItau BBADowngrades
GGALItau BBADowngrades
BMAItau BBADowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

8-K from Lumber Liquidators Shows Co. Issued Response Relating to Relabeling of Certain Engineered Hardwood Floor Products

Macquarie Discusses Hurricane Season And Stock Plays